Quantitative Diagnostics of Parkinsonian Syndromes Using Multi-modal Neuroimaging and Deep Learning
The goals of this study are: 1) to identify biomarkers using neuroimaging that are associated with progression rate using statistical methods, and 2) to identify biomarkers that are associated with the differential diagnosis of Parkinson's disease and atypical parkinsonism.
⁃ For Aim 1:
• Diagnosis of Parkinson disease
• Existence of sufficient clinical data from previous UTS Southwestern longitudinal study to determine progression rate (categorized as fast or slow)
• Availability of suitable matched participant in the alternate progression group (fast or slow)
• Willingness to participate in the imaging studies required for this study and to provide written informed consent
⁃ For Aim 2:
⁃ PD subjects will be recruited in accordance with the MDS Clinical Diagnostic Criteria for PD.
• Duration of PD (since diagnosis) is \< 5 years
• Willing to participate in imaging and clinical scoring visits, and provide written informed consent
• Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move)
⁃ MSA subjects will be recruited in accordance with the Second Consensus Statement on Diagnosis of Multiple System Atrophy.
• Duration of MSA (since diagnosis) is \< 5 years
• Willing to participate in imaging and clinical scoring visits, and provide written informed consent
• Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move away during the study)
⁃ PSP subjects will be recruited in accordance with the MDS Criteria for Diagnosis of Progressive Supranuclear Palsy and must meet the designation of probable PSP for inclusion.
• Willing to participate in imaging and clinical scoring visits, and provide written informed consent
• Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move away during the study)
⁃ Control subjects will be recruited who meet the following criteria:
• Roughly age and sex matched with the subjects in the PD cohort
• No history or examination findings suggestive of any neurodegenerative disease
• Normal gait, balance, and eye movements for age
• No clinical evidence for symptomatic orthostatic hypotension
• Willing to participate in imaging and clinical scoring visits, and provide written informed consent
• Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move away during the study)